Incannex Healthcare (IXHL) Return on Sales (2024 - 2025)
Incannex Healthcare (IXHL) posted Return on Sales of 5.45% for Q2 2025, down 11.0% sequentially from 4.91% in Q4 2024.
Incannex Healthcare (IXHL) Return on Sales (2024 - 2025) Analysis & Trends
Incannex Healthcare has reported Return on Sales for 2 years, with the latest figure at 5.45% in Q2 2025.
- Quarterly Return on Sales changed N/A year-over-year to 5.45% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 5.45% (changed N/A YoY) and the FY2025 annual result came in at 5.45%, up 993.0% from the prior year.
- Return on Sales eased to 5.45% in Q2 2025 per IXHL's latest filing, from 4.91% in the prior quarter.
- Over five years, Return on Sales peaked at 0.73% in Q3 2024 and troughed at 5.45% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 0.00% |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 0.00% |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 0.00% |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 0.00% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 0.00% |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 0.00% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 0.00% |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Incannex Healthcare | 42.87 Mn | 42.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -5.45% |
| Dec 31, 2024 | -4.91% |
| Sep 30, 2024 | -0.73% |